Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has been given a $73.00 price target by equities researchers at Canaccord Genuity in a research report issued to clients and investors on Thursday. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity’s price objective indicates a potential upside of 24.36% from the company’s previous close.
Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald restated a “buy” rating and set a $62.00 target price on shares of Aerie Pharmaceuticals in a research report on Wednesday, October 11th. HC Wainwright set a $69.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Stifel Nicolaus restated a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a research report on Friday, July 28th. Cowen and Company restated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Thursday, October 5th. Finally, Mizuho restated a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a research report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $71.43.
Aerie Pharmaceuticals (AERI) opened at $58.70 on Thursday. Aerie Pharmaceuticals has a 12 month low of $35.20 and a 12 month high of $66.25. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78.
ILLEGAL ACTIVITY NOTICE: This report was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://stocknewstimes.com/2017/11/18/aerie-pharmaceuticals-inc-aeri-pt-set-at-73-00-by-canaccord-genuity.html.
Several institutional investors have recently added to or reduced their stakes in AERI. BlackRock Inc. boosted its position in shares of Aerie Pharmaceuticals by 113,376.8% in the 1st quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock worth $117,951,000 after buying an additional 2,598,596 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Aerie Pharmaceuticals by 55.0% in the 2nd quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock worth $113,446,000 after buying an additional 766,300 shares in the last quarter. Senzar Asset Management LLC acquired a new position in Aerie Pharmaceuticals in the 2nd quarter valued at about $20,568,000. Broadfin Capital LLC acquired a new position in Aerie Pharmaceuticals in the 2nd quarter valued at about $16,291,000. Finally, AXA acquired a new position in Aerie Pharmaceuticals in the 2nd quarter valued at about $10,961,000. Institutional investors and hedge funds own 95.71% of the company’s stock.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.